ARCHIVES

NCI Names 15 to Director’s Consumer Liaison Group.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma

December 31, 2010

Early HER2 Positive Patients At Higher Risk of Recurrence

January 30, 2009

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

In brief: Cancer Investment “Drop In The Bucket,” OMB Is The “Second Greatest Kill,” Pepper Says

August 10, 1979

In Brief: Goldman Named Director, Albert Einstein Cancer Center; Wiernik Resumes Post

October 20, 1995

DCT Board Ok’s concept For In Vivo Combination Studies

November 23, 1990